cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
I Mab
8 own
3 watching
Current Price
$1.77
$-0.08
(-4.32%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
26.6M
52-Week High
52-Week High
4.54000
52-Week Low
52-Week Low
1.16000
Average Volume
Average Volume
0.2M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
20.367
iconMarket Capitalization26.6M
icon52-Week High4.54000
icon52-Week Low1.16000
iconAverage Volume0.2M
iconDividend Yield--
iconP/E Ratio20.367
What does the I Mab do?
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People s Republic of China.
Read More
News & Events about I Mab.
PR Newswire
8 months ago
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC PR Newswire GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire...
PR Newswire
10 months ago
I-MAB Filed 2022 Annual Report on Form 20-F I-MAB Filed 2022 Annual Report on Form 20-F PR Newswire GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ('I-Mab' or the 'Company') (Nasdaq: IMAB), a clinical-stage...
PR Newswire
10 months ago
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 PR Newswire GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire...
PR Newswire
10 months ago
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon PR Newswire GAITHERSBURG, Md. and SHANGHAI, April 25, 2023 Award is an important victory for I-Mab and its shareholders on multiple...
PR Newswire
10 months ago
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China PR Newswire GAITHERSBURG, Md. and SHANGHAI, April 24, 2023...
Frequently Asked Questions
Frequently Asked Questions
What is I Mab share price today?
plus_minus_icon
Can Indians buy I Mab shares?
plus_minus_icon
How can I buy I Mab shares from India?
plus_minus_icon
Can Fractional shares of I Mab be purchased?
plus_minus_icon
What are the documents required to start investing in I Mab stocks?
plus_minus_icon
What is today’s traded volume of I Mab?
plus_minus_icon
What is today’s market capitalisation of I Mab?
plus_minus_icon
What is the 52-Week High and Low Range of I Mab?
plus_minus_icon
What percentage is I Mab down from its 52-Week High?
plus_minus_icon
What percentage is I Mab up from its 52-Week Low?
plus_minus_icon
Current Price
$1.77
$-0.08
(-4.32%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00